title: [ANOCEF guidelines for the management of brain metastases].
abstract: The incidence of brain metastases is increasing because of the use of new therapeutic agents, which allow an improvement of overall survival, but with only a poor penetration into the central nervous system brain barriers. The management of brain metastases has changed due to a better knowledge of immunohistochemical data and molecular biological data, the development of new surgical, radiotherapeutic approaches and improvement of systemic treatments. Most of the time, the prognosis is still limited to several months, nevertheless, prolonged survival may be now observed in some sub-groups of patients. The main prognostic factors include the type and subtype of the primitive, age, general status of the patient, number and location of brain metastases, extracerebral disease. The multidisciplinary discussion should take into account all of these parameters. We should notice also that treatments including surgery or radiotherapy may be proposed in a symptomatic goal in advanced phases of the disease underlying the multidisciplinary approach until late in the evolution of the disease. This article reports on the ANOCEF (French neuro-oncology association) guidelines. The management of brain metastases of breast cancers and lung cancers are discussed in the same chapter, while the management of melanoma brain metastases is reported in a separate chapter due to different responses to the brain radiotherapy.
authors: Neuro-oncologie, département de neurochirurgie, hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille cedex, France; Oncologie médicale, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France; Laboratoire Prism, université Lille 1, Inserm U1192, bâtiment SN3 1(er) étage, 59655 Villeneuve d'Ascq cedex, France; Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC) , 13273 Marseille cedex 09, France. Electronic address: emilie.lerhun@chru-lille.fr.
authors: É
authors: É
authors: Le Rhun
authors: Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC) , 13273 Marseille cedex 09, France; Département de radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Réunion de concertation pluridisciplinaire de neuro-oncologie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
authors: F
authors: F
authors: Dhermain
authors: Département universitaire de radiothérapie, centre de lutte contre le cancer Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; Laboratoire EA 3430, fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, 4, rue Kirschleger, 67085 Strasbourg cedex, France.
authors: G
authors: G
authors: Noël
authors: Département de neurochirurgie, hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille cedex, France.
authors: N
authors: N
authors: Reyns
authors: Service de neurologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris (AP-HP), 125, rue de Stalingrad, 93009 Bobigny cedex, France.
authors: A
authors: A
authors: Carpentier
authors: Département de neurochirurgie, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France.
authors: E
authors: E
authors: Mandonnet
authors: Département de neurologie 2, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Département de radiothérapie, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Université Pierre-et-Marie-Curie Paris VI, 4, place Jussieu, 75005 Paris, France.
authors: S
authors: S
authors: Taillibert
authors: Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC) , 13273 Marseille cedex 09, France; Département de neurochirurgie, centre hospitalo-universitaire La Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France; Centre de recherche en oncologie et oncopharmacologie (CRO2), faculté de médecine Timone, université Aix-Marseille, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France; Inserm U911, faculté de médecine Timone, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France.
authors: P
authors: P
authors: Metellus
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003663:Decision Trees; D019468:Disease Management; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy; D019635:Neurosurgical Procedures; D010166:Palliative Care; D018579:Patient Selection; D011379:Prognosis; D011788:Quality of Life; D016634:Radiosurgery; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents
keywords: Brain metastases; Breast cancer; Cancer du poumon; Cancer du sein; Chemotherapy; Chimiothérapie; Chirurgie; Lung cancer; Melanoma; Mélanome; Métastases cérébrales; Quality of life; Qualité de vie; Radiotherapy; Radiothérapie; Soins de support; Supportive care; Surgery; Targeted therapy; Thérapie ciblée